Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Open-label, Phase 1a / 1b Dose Escalation and Expansion Cohort Study of DM919, a Novel Anti-MICA/B Antibody, as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT06328673 is registered in ClinicalTrials.gov with D2M Biotherapeutics Inc. as lead sponsor.

NCT NCT06328673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06328673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Open-label, Phase 1a / 1b Dose Escalation and Expansion Cohort Study of DM919, a Novel Anti-MICA/B Antibody, as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Lead sponsor
D2M Biotherapeutics Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 9, 2024
Completion date
March 1, 2026
Enrollment
160 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor